Latest Neurochemistry Stories

Inspired by nature, researchers design tiny, synthetic pores that mimic important features of cellular ion channels and other molecular channels Inspired by nature, an international research team has created synthetic pores that mimic the activity of cellular ion channels, which play a vital role in human health by severely restricting the types of materials allowed to enter cells. The pores the scientists built are permeable to potassium ions and water, but not to other ions such as...

Novel system will help treat diseases like Parkinson's, Tourette's and depression Mayo Clinic researchers have found a novel way to monitor real-time chemical changes in the brains of patients undergoing deep brain stimulation (DBS). The groundbreaking insight will help physicians more effectively use DBS to treat brain disorders such as Parkinson's disease, depression and Tourette syndrome. The findings are published in the journal Mayo Clinic Proceedings. Journalists: For multimedia...

(Ivanhoe Newswire) – Parkinson's, Tourette Syndrome and Depression.  They are a debilitating disease and they also share something else in common, a surplus or deficiency of neurochemicals in the brain. Now, researchers have found a novel way to monitor real-time chemical changes in the brains of patients undergoing deep brain stimulation. The research conducted by the Mayo Clinic will help physicians more effectively use DBS to treat brain disorders. "We can learn what...

Researchers at the University of California, San Diego School of Medicine have uncovered a new signal transduction pathway specifically devoted to the regulation of alternative RNA splicing, a process that allows a single gene to produce or code multiple types of protein variants. The discovery, published in the June 27, 2012 issue of Molecular Cell, suggests the new pathway might be a fruitful target for new cancer drugs. Signal transduction in the cell involves kinases and phosphatases,...

New approach reported in Restorative Neurology and Neuroscience Studies suggest that neurotrophic factors, which play a role in the development and survival of neurons, have significant therapeutic and restorative potential for neurologic diseases such as Huntington's disease. However, clinical applications are limited because these proteins cannot easily cross the blood brain barrier, have a short half-life, and cause serious side effects. Now, a group of scientists has successfully...

SUNNYVALE, Calif., June 6, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing drug and diagnostic products for the treatment of Parkinson's disease and other nervous system disorders including Traumatic Brain Injury, today announced that it has been selected to participate in the National Investment Banking Association's 122nd Conference in New York City at Le Park Meridien Hotel June 7-8, 2012. Mr. Gerald Commissiong, Amarantus'...

COLORADO SPRINGS, Colo., May 29, 2012 /PRNewswire/ -- Cannabis Science, Inc. (CBIS.OB), a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to provide insight on the upcoming release of its new over-the-counter skin and nutraceutical product line to be branded "Phytiva" through its newest venture Phytiva Pharmaceuticals Inc. The Company is working as fast as it can to make its cannabis-based formulations that target critical ailments...

Curran, a psychiatrist, is known for his outspoken advocacy for people with addiction.As a founding member of Physicians and Nurses Against Tobacco, Dr. Curran has worked to engage spiritual leaders in the fight against tobacco industry. (PRWEB) May 27, 2012 A United States Congressional candidate is taking on the Pfizer Corporation and its ED commercials as one of his campaign issues. "These commercials are embarrassing. In less than thirty seconds these ads violate innocence, decency,...

SUNNYVALE, Calif., May 9, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the treatment of Parkinson's disease and other nervous system disorders, today announced that it has been selected to participate in the Wall Street 1-2-1 Conference in Orlando, Florida at the Rosen Shingle Creek Resort May 8-11, 2012. Mr. Gerald Commissiong, Amarantus' President & CEO, will be a...

SUNNYVALE, Calif., May 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the treatment of Parkinson's disease and other nervous system disorders, today announced that it has been selected to present in the Emerging Companies Showcase at the New York Biotechnology Association's 21st Annual Meeting on May 2nd, 2012 in New York City at the Marriott Marquis Hotel. Mr....